

Cover Letter.

Name of Journal: *World Journal of Clinical Oncology*

ESPS Manuscript NO: 20645

Manuscript Type: Editorial

Dear Editor,

It is my pleasure to submit to your prestigious journal *World Journal of Clinical Oncology* the revised editorial with ESPS manuscript NO: 20645 entitled “Sequential treatment in disseminated well- and intermediate-differentiated pancreatic neuroendocrine tumors: common sense or low rationale?”

We have modified all the suggestions performed by the reviewers.

95% confident interval has been replaced through all the text by 95%CI following suggestions.

In addition, all comments performed by the editorial team have been addressed. In this sense, we have added the conflict of interest, author contribution, core tip, and modified the reference numbers in square brackets in superscript through out the whole text.

In addition an audio core tip file is also attached

We hope that by the new added parts that are enriching the quality of the article, it could be accepted for publication in *World Journal of Clinical Oncology*.

With my warmest regards



Yours sincerely,
Enrique Grande MD
Department of Medical Oncology
Hospital Ramón y Cajal
Madrid, Spain

Answer to chief editor:

Dear Dr. Ji,

I gladly accept and welcome the suggestion made by the chief editor. In fact, this is a very good observation that definitely further clarifies

Enclosed you can find the new version of the manuscript with changes highlighted in red. We have added to the legend of Figure 2 the following sentence:

'Figure 2 Different sequential alternatives to be used in advanced pancreatic neuroendocrine tumor patients based on approved agents. The term 'Chemotherapy' may include streptozocin +/- 5-fluorouracil or doxorubicin, or temozolomide +/- capecitabine'

We hope that now the manuscript could be finally accepted

Best regards

Enrique